,3 Current RCC therapies target two main features of the tumor microenvironment (TME): the immune system (e.g., immune checkpoint inhibitors) and the tumor vasculature (e.g., blockers of the vascular endothelial growth factor (VEGF)/VEGF receptor(VEGFR) axis).4 This evidence concerns the gene KDR and neoplasm.